Compare · GILD vs MESO
GILD vs MESO
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Mesoblast Limited (MESO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and MESO operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $166.72B, about 74.6x MESO ($2.24B).
- Over the past year, GILD is up 24.1% and MESO is up 11.0% - GILD leads by 13.1 points.
- MESO has been more active in the news (10 items in the past 4 weeks vs 7 for GILD).
- GILD has more recent analyst coverage (25 ratings vs 14 for MESO).
- Company
- Gilead Sciences Inc.
- Mesoblast Limited
- Price
- $134.23-1.50%
- $17.36-2.75%
- Market cap
- $166.72B
- $2.24B
- 1M return
- +5.49%
- +26.53%
- 1Y return
- +24.06%
- +11.00%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- 2015
- News (4w)
- 7
- 10
- Recent ratings
- 25
- 14
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Mesoblast Limited
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Latest GILD
- Chief Financial Officer Dickinson Andrew D sold $389,777 worth of shares (3,000 units at $129.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 168,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna sold $389,758 worth of shares (3,000 units at $129.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 121,234 units (SEC Form 4)
- Gilead Sciences upgraded by HSBC Securities with a new price target
- Chairman & CEO O'Day Daniel Patrick sold $1,894,400 worth of shares (15,000 units at $126.29) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 607,133 units (SEC Form 4)
- U.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
- Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
- European Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
- Chief Comm & Corp Aff Officer Mercier Johanna sold $371,762 worth of shares (3,000 units at $123.92) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 124,234 units (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $376,200 worth of shares (3,000 units at $125.40) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 171,646 units (SEC Form 4)
- U.S. FDA Accepts Gilead's Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
Latest MESO
- SEC Form 6-K filed by Mesoblast Limited
- SEC Form 6-K filed by Mesoblast Limited
- Mesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Pain
- SEC Form 6-K filed by Mesoblast Limited
- SEC Form 4 filed by Chief Financial Officer Obrien James Michael
- Ryoncil® Delivers Net Revenue of US$36M for the Fourth Quarter Ended 30 June 2026
- SEC Form 6-K filed by Mesoblast Limited
- Mesoblast Receives BLA Filing Number and Requests Modular Review for Rexlemestrocel-L in Patients with End-Stage Heart Failure and LVADs
- SEC Form 6-K filed by Mesoblast Limited
- Mesoblast Draws US$50 Million from Five-Year Non-Dilutive Facility